| Name | Title | Contact Details |
|---|
UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.
The UroLift System is an FDA Cleared, revolutionary minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) or an enlarged prostate.
Minakem is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ferring Research Institute is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.